Is Bio-Techne Corporation (TECH) A Smart Long-Term Buy?

This post was originally published on this site

Alger, an investment management firm, published its “Alger Small Cap Focus Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. During the quarter, the largest portfolio sector weightings were Health Care and Information Technology. The largest sector overweight was Health Care. Class A shares of the Alger Small Cap Focus Fund underperformed the Russell 2000 Growth Index during the first quarter of 2021. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

Alger Small Cap Focus Fund, in their Q1 2021 investor letter, mentioned Bio-Techne Corporation (NASDAQ: TECH) and shared their insights on the company. Bio-Techne Corporation is a Minneapolis, Minnesota-based biotechnology company chain that currently has a $16.2 billion market capitalization. Since the beginning of the year, TECH delivered a 31.81% return, extending its 12-month gains to 101.43%. As of April 16, 2021, the stock closed at $418.55 per share.

Here is what Alger Small Cap Focus Fund has to say about Bio-Techne Corporation in their Q1 2021 investor letter:

“Bio-Techne Corporation was among the top contributors to performance during the first quarter. Bio-Techne develops, manufactures and sells biotechnology reagents, clinical diagnostic products and instruments for medical research and clinical diagnostic applications. With its deep product portfolio and application expertise, Bio-Techne provides life science customers with innovative, high-quality scientific tool s to better understand biological processes and drive discovery of diagnostic and therapeutic products. Bio-Techne also sells a portfolio of assays, or clinical molecular diagnostic oncology products, including a test used in the diagnosis of prostate cancer. Shares of Bio-Techne outperformed during the first quarter due to stronger-than-expected earnings for the company’s fiscal second quarter. Bio-Techne delivered core organic growth of 19%, substantially exceeding expectations. Bio-Techne experienced a faster-than expected rebound in demand from academic customers, while demand from biopharmaceutical customers remained robust. This stronger revenue performance drove higher margins and earnings in the quarter.”


Our calculations show that Bio-Techne Corporation (NASDAQ: TECH) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Bio-Techne Corporation was in 24 hedge fund portfolios, compared to 30 funds in the third quarter. TECH delivered a 20.37% return in the past 3 months.

The top 10 stocks among hedge funds returned 231.2% between 2015 and 2020, and outperformed the S&P 500 Index ETFs by more than 126 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Here you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 15 best innovative stocks to buy to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.